Renascience
4889.TPharmaceutical
Filed as Renascience, Inc (2022-06–2022-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Operating income | −¥357m | −¥179m | −¥252m | −¥334m | −¥211m | −¥86m |
| Ordinary income | −¥300m | −¥179m | −¥252m | −¥334m | −¥242m | −¥91m |
| Total assets | ¥3.5bn | ¥1.9bn | ¥2.1bn | ¥2.3bn | ¥2.4bn | ¥1.1bn |
| Net assets / equity | ¥3.3bn | ¥1.7bn | ¥1.6bn | ¥1.9bn | ¥2.2bn | ¥562m |
| Operating cash flow | −¥291m | −¥176m | −¥231m | −¥285m | −¥230m | −¥89m |
| EPS (basic) | ¥-23.39 | ¥8.92 | ¥-20.32 | ¥-26.42 | ¥-22.33 | ¥-10.19 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 99 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 57 figures · EDINET |
| 2024-04-01 → 2025-03-31 | AnnualAmended | 101 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 101 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 59 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 100 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 39 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 61 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 37 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 96 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 39 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 61 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 37 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 92 figures · EDINET |
2 more reports are still being processed.